Mesoblast To Issue 10.2 Million Shares to Osiris Therapeutics Following US FDA Approval of Cell Treatment; Shares Fall 6%
Mesoblast To Issue 10.2 Million Shares to Osiris Therapeutics Following US FDA Approval of Cell Treatment; Shares Fall 6%
Mesoblast将向Osiris Therapeutics发行1020万股股份,此举是在美国FDA批准电芯治疗后;股价下跌6%
Unity Software(U.US) reported fourth-quarter financial results after the market close on Monday. Here's a rundown of the report.Q4 Earnings: Unity said fourth-quarter revenue increased 35% year-over-year to $609 million, beating the consensus estimate of $562.71 million. The company reported a quarterly loss of 66 cents per share.
登录免费看全文
登录/注册